Would you consider bevacizumab for a patient with SCLC who has asymptomatic brain metastasis progression after CNS radiation while on maintenance immunotherapy?

I wouldn't do it now that we have agents such as tarlatamab, which has better CNS penetrance. Adding bevacizumab to atezo does have a rationale and theoretical benefit. The CeLEBrATE study, which was recently published, showed synergy between chemo, atezo, and bev, and patients with asymptomatic brain mets were included, but the efficacy of this 4-drug combo single-arm phase 2 study was rather underwhelming. Additionally, the BEAT-SC study, which compared the sa...